BACKGROUND: Matched related donor (MRD) hematopoietic stem cell transplantation (HSCT) is a successful treatment for chronic granulomatous disease (CGD), but the safety and efficacy of HSCT from unrelated donors is less certain. OBJECTIVE: We evaluated the outcomes and overall survival in patients with CGD after HSCT. METHODS: We report the outcomes for 11 children undergoing HSCT from an MRD (n = 4) or an HLA-matched unrelated donor (MUD) (n = 7); 9 children were boys, and the median age was 3.8 years (range, 1-13 years). We treated both X-linked (n = 9) and autosomal recessive (n = 2) disease. Nine children had serious clinical infections before transplantation. The conditioning regimens contained busulfan, cyclophosphamide, cytarabine, or fludarabine according to the donor used. All patients received alemtuzumab (anti-CD52 antibody). Additional graft-versus-host disease (GvHD) prophylaxis included cyclosporine and methotrexate for MUD recipients and cyclosporine and prednisone for MRD recipients. RESULTS: Neutrophil recovery took a median of 16 days (range, 12-40 days) and 18 days (range, 13-24 days) for MRD and MUD recipients, respectively. Full donor neutrophil engraftment occurred in 9 patients, and 2 had stable mixed chimerism; all patients had sustained correction of neutrophil oxidative burst defect. Four patients had grade I skin acute GVHD responding to topical treatment. No patient had grade II to IV acute GvHD or chronic GvHD. All patients are alive between 1 and 8 years after HSCT. CONCLUSION: For CGD, equivalent outcomes can be obtained with MRD or MUD stem cells, and HSCT should be considered an early treatment option.
BACKGROUND: Matched related donor (MRD) hematopoietic stem cell transplantation (HSCT) is a successful treatment for chronic granulomatous disease (CGD), but the safety and efficacy of HSCT from unrelated donors is less certain. OBJECTIVE: We evaluated the outcomes and overall survival in patients with CGD after HSCT. METHODS: We report the outcomes for 11 children undergoing HSCT from an MRD (n = 4) or an HLA-matched unrelated donor (MUD) (n = 7); 9 children were boys, and the median age was 3.8 years (range, 1-13 years). We treated both X-linked (n = 9) and autosomal recessive (n = 2) disease. Nine children had serious clinical infections before transplantation. The conditioning regimens contained busulfan, cyclophosphamide, cytarabine, or fludarabine according to the donor used. All patients received alemtuzumab (anti-CD52 antibody). Additional graft-versus-host disease (GvHD) prophylaxis included cyclosporine and methotrexate for MUD recipients and cyclosporine and prednisone for MRD recipients. RESULTS: Neutrophil recovery took a median of 16 days (range, 12-40 days) and 18 days (range, 13-24 days) for MRD and MUD recipients, respectively. Full donor neutrophil engraftment occurred in 9 patients, and 2 had stable mixed chimerism; all patients had sustained correction of neutrophil oxidative burst defect. Four patients had grade I skin acute GVHD responding to topical treatment. No patient had grade II to IV acute GvHD or chronic GvHD. All patients are alive between 1 and 8 years after HSCT. CONCLUSION: For CGD, equivalent outcomes can be obtained with MRD or MUD stem cells, and HSCT should be considered an early treatment option.
Authors: H L Malech; P B Maples; N Whiting-Theobald; G F Linton; S Sekhsaria; S J Vowells; F Li; J A Miller; E DeCarlo; S M Holland; S F Leitman; C S Carter; R E Butz; E J Read; T A Fleisher; R D Schneiderman; D E Van Epps; S K Spratt; C A Maack; J A Rokovich; L K Cohen; J I Gallin Journal: Proc Natl Acad Sci U S A Date: 1997-10-28 Impact factor: 11.205
Authors: Ann M Leen; G Doug Myers; Uluhan Sili; M Helen Huls; Heidi Weiss; Kathryn S Leung; George Carrum; Robert A Krance; Chung-Che Chang; Jeffrey J Molldrem; Adrian P Gee; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney; Catherine M Bollard Journal: Nat Med Date: 2006-09-24 Impact factor: 53.440
Authors: J Liese; S Kloos; V Jendrossek; T Petropoulou; U Wintergerst; G Notheis; M Gahr; B H Belohradsky Journal: J Pediatr Date: 2000-11 Impact factor: 4.406
Authors: Helen E Heslop; Karen S Slobod; Martin A Pule; Gregory A Hale; Alexandra Rousseau; Colton A Smith; Catherine M Bollard; Hao Liu; Meng-Fen Wu; Richard J Rochester; Persis J Amrolia; Julia L Hurwitz; Malcolm K Brenner; Cliona M Rooney Journal: Blood Date: 2009-10-30 Impact factor: 22.113
Authors: Stefan Stein; Marion G Ott; Stephan Schultze-Strasser; Anna Jauch; Barbara Burwinkel; Andrea Kinner; Manfred Schmidt; Alwin Krämer; Joachim Schwäble; Hanno Glimm; Ulrike Koehl; Carolin Preiss; Claudia Ball; Hans Martin; Gudrun Göhring; Kerstin Schwarzwaelder; Wolf-Karsten Hofmann; Kadin Karakaya; Sandrine Tchatchou; Rongxi Yang; Petra Reinecke; Klaus Kühlcke; Brigitte Schlegelberger; Adrian J Thrasher; Dieter Hoelzer; Reinhard Seger; Christof von Kalle; Manuel Grez Journal: Nat Med Date: 2010-01-24 Impact factor: 53.440
Authors: L B K R Jones; P McGrogan; T J Flood; A R Gennery; L Morton; A Thrasher; D Goldblatt; L Parker; A J Cant Journal: Clin Exp Immunol Date: 2008-05 Impact factor: 4.330
Authors: Mark Parta; Corin Kelly; Nana Kwatemaa; Narda Theobald; Diane Hilligoss; Jing Qin; Douglas B Kuhns; Christa Zerbe; Steven M Holland; Harry Malech; Elizabeth M Kang Journal: J Clin Immunol Date: 2017-07-28 Impact factor: 8.317
Authors: Lukas Schwab; Luise Goroncy; Senthilnathan Palaniyandi; Sanjivan Gautam; Antigoni Triantafyllopoulou; Attila Mocsai; Wilfried Reichardt; Fridrik J Karlsson; Sabarinath V Radhakrishnan; Kathrin Hanke; Annette Schmitt-Graeff; Marina Freudenberg; Friederike D von Loewenich; Philipp Wolf; Franziska Leonhardt; Nicoleta Baxan; Dietmar Pfeifer; Oliver Schmah; Anne Schönle; Stefan F Martin; Roland Mertelsmann; Justus Duyster; Jürgen Finke; Marco Prinz; Philipp Henneke; Hans Häcker; Gerhard C Hildebrandt; Georg Häcker; Robert Zeiser Journal: Nat Med Date: 2014-05-18 Impact factor: 53.440